 "Covaxin")
Bharat Biotech on Friday said that it is slowing down Covaxin production across sites as it sees decrease in demand. The company added that it has finished supply obligations to various procurement agencies.
"For the coming period, the company will focus on pending facility maintenance, process and facility optimization activities," the company said.
As all existing facilities were repurposed for the manufacture of Covaxin, with continuous production during the past year, to meet the public health emergency of COVID-19, these upgrades were due, it said.
In December, Serum Institute of India had cut down Covishield production by half after it piled up inventory
